Celerion Adds Containment Room

Article

Modular containment room at Belfast facility allows studies of biologics and vaccines.

Celerion added a containment room at the Belfast, Northern Ireland, UK facility, the company announced in a press release. The new containment room will allow Celerion to develop programs that require studies utilizing biologics, as well as vaccines with primary and secondary containment.

The modular facility uses a negative-pressure processing room that houses a Biosafety Level (BSL-2) cabinet. The room enables processing of live class 2 and class 3 biological products.

Celerion’s facility in Belfast also has extensive early-stage clinical capabilities based on First-In-Human experience with both NCEs and biologics, as well as bioequivalence, biosimilars, obesity, ophthalmic, and gastro-intestinal studies.

Recent Videos
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content